Reversal of multidrug resistance of tumor cells by anti-mdr1 ribozyme.
- Author:
Peng GAO
1
;
Geng-Yin ZHOU
;
Qing-Hui ZHANG
;
Cheng-Jun ZHOU
;
Jun-Hui ZHEN
;
Yan-Lin SUN
Author Information
- Publication Type:Journal Article
- MeSH: ATP-Binding Cassette, Sub-Family B, Member 1; genetics; Antineoplastic Agents; pharmacology; Breast Neoplasms; genetics; pathology; therapy; Doxorubicin; pharmacology; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Transfer Techniques; Genes, MDR; genetics; Genetic Vectors; Humans; RNA, Catalytic; genetics; Retroviridae; genetics
- From: Chinese Journal of Pathology 2004;33(3):251-254
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo stably reverse the multidrug resistance (MDR) of breast carcinoma cells in vitro.
METHODSTwo anti-mdr-1 ribozyme plasmids, RZ196 and RZ179, were constructed with EGFP as reporter gene and transfected into drug-resistant breast carcinoma cells in vitro. The expression of EGFP was observed by laser confocal microscopy. Flow cytometry, RT-PCR and Rhodamine123 efflux assay were used to detect P-glyco protein (p-gp) and mdr-1 mRNA.
RESULTSAfter transfection with RZ196 and RZ179, the mdr-1 indices were reduced from 2.20 to 0.76 and 1.40, the expression rates of p-gp were reduced from 55.0% to 4.6% and 18.2%, the fluorescence intensity increased from 22.0% to 46.2% and 70.1%, TCL reduced from 75% to 28% and 43% respectively. In addition, the expression of ribozyme plasmid in tumor cells was stable under G418 selection. After two months, the mdr-1 indices remained at 0.81 and 1.47 in the cells transfected RZ196 and RZ179 respectively. The expression rates of p-gp were 5.2% and 19.5% and the Rh123 fluorescence intensity was 51.4% and 71.6% respectively.
CONCLUSIONSBoth anti-mdr-1 ribozyme RZ196 and RZ179 can stably reverse MDR phenotype of breast carcinoma cells in vitro. RZ196 construct appears to be more effective.